Latest news with #STAMP
Yahoo
19-03-2025
- Entertainment
- Yahoo
Today's Wordle answer for Tuesday, March 18
When you buy through links on our articles, Future and its syndication partners may earn a commission. There's a hint for today's Wordle just below, designed to give you some guessing guidance while still leaving you enough room to work your puzzle solving magic. Use it before you've tried a single word if you want to give yourself a flying start, or save it for later if those yellow letters refuse to behave. The March 18 (1368) answer is here too, just in case. The single yellow letter in my opening row didn't give me a lot of hope, but I persevered and eventually found myself with a full set of winning greens after a few more attempts. Make sure you take a peek at today's clue if you'd like a better first line than I had. A mechanism for measuring time, but not a clock. If you need to know when an egg's cooked or a test's over, this is the thing to use. No, there is not a double letter in today's puzzle. A good starting word can be the difference between victory and defeat with the daily puzzle, but once you've got the basics, it's much easier to nail down those Wordle wins. And as there's nothing quite like a small victory to set you up for the rest of the day, here are a few tips to help set you on the right path: A good opening guess should contain a mix of unique consonants and vowels. Narrow down the pool of letters quickly with a tactical second guess. Watch out for letters appearing more than once in the answer. There's no racing against the clock with Wordle so you don't need to rush for the answer. Treating the game like a casual newspaper crossword can be a good tactic; that way, you can come back to it later if you're coming up blank. Stepping away for a while might mean the difference between a win and a line of grey squares. Another win? Another win. The answer to the March 18 (1368) Wordle is TIMER. Past Wordle answers can give you some excellent ideas for fun starting words that keep your daily puzzle-solving fresh. They are also a good way to eliminate guesses for today's Wordle, as the answer is unlikely to be repeated. Here are some recent Wordle answers: March 17: LASSO March 16: STAMP March 15: LADLE March 14: PIECE March 13: CHASE March 12: MANGO March 11: TRACK March 10: SPITE March 9: GREED March 8: NAVEL Wordle gives you six rows of five boxes each day, and you'll need to work out which secret five-letter word is hiding inside them to keep up your winning streak. You should start with a strong word like ARISE, or any other word that contains a good mix of common consonants and multiple vowels. You'll also want to avoid starting words with repeating letters, as you're wasting the chance to potentially eliminate or confirm an extra letter. Once you hit Enter, you'll see which ones you've got right or wrong. If a box turns ⬛️, it means that letter isn't in the secret word at all. 🟨 means the letter is in the word, but not in that position. 🟩 means you've got the right letter in the right spot. Your second guess should compliment the starting word, using another "good" word to cover any common letters you missed last time while also trying to avoid any letter you now know for a fact isn't present in today's answer. With a bit of luck, you should have some coloured squares to work with and set you on the right path. After that, it's just a case of using what you've learned to narrow your guesses down to the right word. You have six tries in total and can only use real words (so no filling the boxes with EEEEE to see if there's an E). Don't forget letters can repeat too (ex: BOOKS). If you need any further advice feel free to check out our Wordle tips, and if you'd like to find out which words have already been used you can scroll to the relevant section above. Originally, Wordle was dreamed up by software engineer Josh Wardle, as a surprise for his partner who loves word games. From there it spread to his family, and finally got released to the public. The word puzzle game has since inspired tons of games like Wordle, refocusing the daily gimmick around music or math or geography. It wasn't long before Wordle became so popular it was sold to the New York Times for seven figures. Surely it's only a matter of time before we all solely communicate in tricolor boxes.
Yahoo
18-03-2025
- Entertainment
- Yahoo
Wordle hints today for #1,368: Clues and answer for Tuesday, March 18
Hey, there! We hope your week is off to a great start. When it's time for a break today, there's a fresh round of Wordle waiting for you. In case you need a helping hand with it, here's our daily Wordle guide with some hints and the answer for Tuesday's puzzle (#1,368). It may be that you're a Wordle newcomer and you're not completely sure how to play the game. We're here to help with that too. Wordle is a deceptively simple daily word game that first emerged in 2021. The gist is that there is one five-letter word to deduce every day by process of elimination. The daily word is the same for everyone. Wordle blew up in popularity in late 2021 after creator Josh Wardle made it easy for players to share an emoji-based grid with their friends and followers that detailed how they fared each day. The game's success spurred dozens of clones across a swathe of categories and formats. The New York Times purchased Wordle in early 2022 for an undisclosed sum. The publication said that players collectively played Wordle 5.3 billion times in 2024. So, it's little surprise that Wordle is one of the best online games and puzzles you can play daily. To start playing Wordle, you simply need to enter one five-letter word. The game will tell you how close you are to that day's secret word by highlighting letters that are in the correct position in green. Letters that appear in the word but aren't in the right spot will be highlighted in yellow. If you guess any letters that are not in the secret word, the game will gray those out on the virtual keyboard. You'll only have six guesses to find each day's word, though you still can use grayed-out letters to help narrow things down. It's also worth remembering that letters can appear in the secret word more than once. Wordle is free to play on the NYT's website and apps, as well as on Meta Quest headsets. The game refreshes at midnight local time. If you log into a New York Times account, you can track your stats, including the all-important win streak. If you have a NYT subscription that includes full access to the publication's games, you don't have to stop after a single round of Wordle. You'll have access to an archive of more than 1,300 previous Wordle games. So if you're a relative newcomer, you'll be able to go back and catch up on previous editions. In addition, paid NYT Games members have access to a tool called the Wordle Bot. This can tell you how well you performed at each day's game. Before today's Wordle hints, here are the answers to recent puzzles that you may have missed: Yesterday's Wordle answer for Monday, March 17 — LASSO Sunday, March 16 — STAMP Saturday, March 15 — LADLE Friday, March 14 — PIECE Thursday, March 13 — CHASE Every day, we'll try to make Wordle a little easier for you. First, we'll offer a hint that describes the meaning of the word or how it might be used in a phrase or sentence. We'll also tell you if there are any double (or even triple) letters in the word. In case you still haven't quite figured it out by that point, we'll then provide the first letter of the word. Those who are still stumped after that can continue on to find out the answer for today's Wordle. This should go without saying, but make sure to scroll slowly. Spoilers are ahead. Here is a hint for today's Wordle answer: Mechanism that either sounds an alarm after a certain period has elapsed or measures how long something takes. There are no repeated letters in today's Wordle answer. The first letter of today's Wordle answer is T. This is your final warning before we reveal today's Wordle answer. No take-backs. Don't blame us if you happen to scroll too far and accidentally spoil the game for yourself. What is today's Wordle? Today's Wordle answer is... TIMER Not to worry if you didn't figure out today's Wordle word. If you made it this far down the page, hopefully you at least kept your streak going. And, hey: there's always another game tomorrow.
Yahoo
17-03-2025
- Entertainment
- Yahoo
Wordle hints today for #1,367: Clues and answer for Monday, March 17
Hey, there! Welcome to the start of a new week. We hope you're well-rested and raring to go. Whenever you need a breather, there's a fresh round of Wordle to enjoy. For those who'd like a helping hand with it, here's our daily Wordle guide with some hints and the answer for Monday's puzzle (#1,367). It may be that you're a Wordle newcomer and you're not completely sure how to play the game. We're here to help with that too. Wordle is a deceptively simple daily word game that first emerged in 2021. The gist is that there is one five-letter word to deduce every day by process of elimination. The daily word is the same for everyone. Wordle blew up in popularity in late 2021 after creator Josh Wardle made it easy for players to share an emoji-based grid with their friends and followers that detailed how they fared each day. The game's success spurred dozens of clones across a swathe of categories and formats. The New York Times purchased Wordle in early 2022 for an undisclosed sum. The publication said that players collectively played Wordle 5.3 billion times in 2024. So, it's little surprise that Wordle is one of the best online games and puzzles you can play daily. To start playing Wordle, you simply need to enter one five-letter word. The game will tell you how close you are to that day's secret word by highlighting letters that are in the correct position in green. Letters that appear in the word but aren't in the right spot will be highlighted in yellow. If you guess any letters that are not in the secret word, the game will gray those out on the virtual keyboard. You'll only have six guesses to find each day's word, though you still can use grayed-out letters to help narrow things down. It's also worth remembering that letters can appear in the secret word more than once. Wordle is free to play on the NYT's website and apps, as well as on Meta Quest headsets. The game refreshes at midnight local time. If you log into a New York Times account, you can track your stats, including the all-important win streak. If you have a NYT subscription that includes full access to the publication's games, you don't have to stop after a single round of Wordle. You'll have access to an archive of more than 1,300 previous Wordle games. So if you're a relative newcomer, you'll be able to go back and catch up on previous editions. In addition, paid NYT Games members have access to a tool called the Wordle Bot. This can tell you how well you performed at each day's game. Before today's Wordle hints, here are the answers to recent puzzles that you may have missed: Yesterday's Wordle answer for Sunday, March 16 — STAMP Saturday, March 15 — LADLE Friday, March 14 — PIECE Thursday, March 13 — CHASE Wednesday, March 12 — MANGO Every day, we'll try to make Wordle a little easier for you. First, we'll offer a hint that describes the meaning of the word or how it might be used in a phrase or sentence. We'll also tell you if there are any double (or even triple) letters in the word. In case you still haven't quite figured it out by that point, we'll then provide the first letter of the word. Those who are still stumped after that can continue on to find out the answer for today's Wordle. This should go without saying, but make sure to scroll slowly. Spoilers are ahead. Here is a hint for today's Wordle answer: Apple TV+ hit _____. There is a pair of repeated letters in today's Wordle answer. The first letter of today's Wordle answer is L. This is your final warning before we reveal today's Wordle answer. No take-backs. Don't blame us if you happen to scroll too far and accidentally spoil the game for yourself. What is today's Wordle? Today's Wordle answer is... LASSO Not to worry if you didn't figure out today's Wordle word. If you made it this far down the page, hopefully you at least kept your streak going. And, hey: there's always another game tomorrow.
Associated Press
27-01-2025
- Business
- Associated Press
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients
Treatment immunobridging analysis, routinely updated for contemporary SARS-CoV-2 variants, compares pemivibart antiviral titers to adintrevimab antiviral titers from the company's previous Phase 2/3 clinical trial of adintrevimab for the treatment of COVID-19 (STAMP), in which adintrevimab conferred a 66% to 74% reduction in risk of hospitalization or death from COVID-19 compared to placebo depending on time of therapy start Most recent updated analysis provided to FDA, incorporating current dominant SARS-CoV-2 variant XEC neutralization data, demonstrated substantially higher pemivibart titers in the critical early phase post-dosing (Days 0-5) as compared to adintrevimab Data provided to FDA includes supportive data showing attractive comparison of antiviral activity between pemivibart and monoclonal antibodies previously authorized for treatment of COVID-19 Pemivibart safety profile demonstrated in the company's CANOPY Phase 3 clinical trial supports the EUA amendment request; further, no additional reports of anaphylaxis have been identified during post-authorization use of PEMGARDA for COVID-19 pre-exposure prophylaxis (PrEP) to date Updated analysis builds upon multiple comparable analyses submitted to the FDA beginning July 2024 for prior SARS-CoV-2 variants, all showing consistent antiviral titer relationships and a favorable risk-benefit profile WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) of an updated immunobridging analysis of pemivibart as ongoing support of a potential amendment to the Emergency Use Authorization (EUA) for pemivibart, a half-life extended investigational monoclonal antibody (mAb), to include the treatment of mild-to-moderate symptomatic COVID-19 in certain immunocompromised patients for whom alternative COVID-19 treatment options are not accessible or clinically appropriate. PEMGARDA™ (pemivibart) received an EUA from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise. This updated treatment immunobridging analysis, incorporating dominant SARS-CoV-2 variant XEC neutralization data, is similar to the approach and data that supported the PEMGARDA PrEP EUA. The updated analysis is in line with the prior, positive treatment immunobridging analyses of pemivibart versus its parent molecule, adintrevimab, and other comparator mAbs based on prior virus variants, previously submitted to the FDA in mid-2024 and late-2024 in support of the company's EUA amendment request for COVID-19 treatment. The comparison between pemivibart and adintrevimab illustrates serum virus neutralizing antibody (sVNA) titers, the clinical measure of antiviral activity, conferred by pemivibart substantially exceed those of adintrevimab for the first four days post dosing, after which titers fall modestly below. As a long-acting mAb, pemivibart would be expected to exert meaningful antiviral activity for many months following a single dose. In the STAMP clinical trial, adintrevimab conferred the majority of its maximum antiviral effect by Day 5 and demonstrated a viral load reduction generally in line with PAXLOVID®1. Because pemivibart is dosed intravenously, higher serum drug concentration and corresponding antiviral activity are delivered immediately, compared to the slower distribution of intramuscularly administered adintrevimab. Pemivibart's pharmacodynamic profile therefore may have some benefit in modifying viral infection and associated clinical outcomes as compared to adintrevimab. Prior randomized control trials of COVID-19 mAbs have underscored the benefit of deploying maximum antiviral activity as early as possible in the treatment of active infection in avoiding hospitalization and adverse morbid/mortal outcomes2. If an EUA amendment for COVID-19 treatment is granted, Invivyd intends to assess the virologic profile of pemivibart in a clinical study designed in collaboration with the FDA. The standing treatment EUA request supporting pemivibart for the treatment of COVID-19 in certain immunocompromised patients for whom alternative COVID-19 treatment options, such as PAXLOVID® (nirmatrelvir) therapy, are not accessible or clinically appropriate, relies on the safety profile and sVNA titers of PEMGARDA demonstrated in the CANOPY Phase 3 clinical trial. Following the four cases of anaphylaxis seen in the CANOPY clinical trial, no reports of anaphylaxis have been identified to date during post-authorization use of PEMGARDA across potentially thousands of PEMGARDA doses administered in clinical practice. 'Current therapies for COVID-19 have significant limitations, for example the drug-drug interaction complications imposed by nirmatrelvir create clinical circumstances in which standard of care may not be possible or appropriate for patients in need. Patients – particularly the millions of Americans who are immunocompromised – desperately need more and better therapeutic options because COVID-19 is not going away. Monoclonal antibodies have been highly attractive therapeutic options in the past and the community would welcome the return of a therapeutic mAb,' said Amesh Adalja, MD, FIDSA, FACP, FACEP, Senior Scholar, Johns Hopkins Center for Health Security. The EUA process does not rely on a statutory timeline such as the timelines embedded into the Prescription Drug User Fee Act (PDUFA)-based regulatory actions such as New Drug Application (NDA) or Biologics License Application (BLA) approval processes. Invivyd initially submitted a package to the FDA in support of a COVID-19 treatment EUA amendment request in July 2024, and since has provided consistent, timely updates to the FDA as SARS-CoV-2 virus variation has presented and as Invivyd has generated data in its ongoing industrial virology effort. Of note, given robust and consistent generation of sVNA titers, the direct expression of antibody antiviral activity, and comparability across multiple antibodies, Invivyd believes that the performance of Invivyd antibodies based on sVNA titers represents a well-supported surrogate endpoint and should be considered for approval beyond EUA to enable pemivibart to remain a long-term option for vulnerable, immunocompromised persons. About PEMGARDA PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1 and XEC. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells. PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19 or post-exposure prophylaxis of COVID-19. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccinations, should receive COVID-19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse events (all grades, incidence ≥2%) observed in participants who have moderate-to-severe immune compromise treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache, and nausea. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning. To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner. PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based on available information including variant susceptibility to PEMGARDA and national variant frequencies. About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit to learn more. Trademarks are the property of their respective owners. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'could,' 'expects,' 'estimates,' 'intends,' 'potential,' 'projects,' and 'future' or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company's ongoing research and development activities, as well as future potential research and development efforts; the company's emergency use authorization (EUA) amendment request for PEMGARDA™ (pemivibart) for the treatment of mild-to-moderate COVID-19 in certain immunocompromised patients, and the company's beliefs regarding data supportive thereof; expectations regarding the duration of antiviral activity of pemivibart, and the potential benefits of pemivibart's pharmacodynamic profile; the company's intention to assess the virologic profile of pemivibart in a clinical study, if an EUA amendment for COVID-19 treatment is granted; expectations regarding the COVID-19 landscape, limitations of current therapies for COVID-19, and the potential of mAbs as a therapeutic option for COVID-19; the company's beliefs about possible regulatory pathways for Invivyd antibodies, and the potential for pemivibart as a long-term option for vulnerable, immunocompromised patients; the company's ongoing industrial virology effort; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents who have moderate-to-severe immune compromise; the company's devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the outcome of the company's EUA amendment request for pemivibart for treatment of mild-to-moderate COVID-19 in certain immunocompromised patients, and the timing thereof; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revised or revoked by the FDA; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for authorization or approval of the company's product candidates; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; changes in the regulatory environment; the timing and progress of the company's discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company's product candidates based on neutralizing activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; the company's reliance on third parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that pemivibart targets remains structurally intact; whether pemivibart or any other product candidate is able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; the company's ability to maintain and expand sales, marketing and distribution capabilities to successfully commercialize PEMGARDA; changes in expected or existing competition; the company's ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, each filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. Contacts: Media Relations (781) 208-1747 2 Ison et al Open Forum Infect Dis. 2023 May 24;10(6):ofad279
